![Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/11/e003743/F1.large.jpg)
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom06UEAAQejo.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig-1639066418797.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_table-1639066418765.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig_thumbnail-1639066418803.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0112-1/MediaObjects/41669_2018_112_Fig2_HTML.png)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
![PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23dbeed54cde655fb6a12697b02c9ff303515da7/11-Table2-1.png)
PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar
![Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/69766215-e264-4caa-b369-dcfa3eeb0100/gr1_lrg.gif)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom0cUEAAIXOn.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![Cancers | Free Full-Text | LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials Cancers | Free Full-Text | LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials](https://www.mdpi.com/cancers/cancers-14-04975/article_deploy/html/images/cancers-14-04975-g001-550.jpg)
Cancers | Free Full-Text | LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
![ESMO 2017: Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067 ESMO 2017: Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1675406399169106850663dcac3f4481b.jpg)
ESMO 2017: Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
![Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post](https://ascopost.com/media/14018767/117-wolchok.jpeg?anchor=center&mode=crop&width=400&height=300&rnd=132835446850000000)
Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204518307009-gr4.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect
![Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig6_HTML.gif)
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
![Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig3_HTML.gif)